Clinical utility of lipoprotein-associated phospholipase A 2 for cardiovascular disease prediction in a multiethnic cohort of women.

Authors

Nancy R. Cook, Brigham and Women's Hospital, Boston, MA
Nina P. Paynter, Brigham and Women's Hospital, Boston, MA
Joann E. Manson, Brigham and Women's Hospital, Boston, MA
Lisa W. Martin, George Washington UniversityFollow
Jennifer Robinson, University of Iowa
Sylvia Wassertheil-Smoller, Albert Einstein College of Medicine, Bronx, NY
Paul M. Ridker, Brigham and Women's Hospital, Boston, MA

Document Type

Journal Article

Publication Date

9-2012

Journal

Clinical Chemistry

Volume

Volume 58, Issue 9

Inclusive Pages

1352-1363

Keywords

Cardiovascular Diseases--enzymology; Ethnic Groups; Lipoproteins--metabolism; Phospholipases A2--metabolism

Comments

This is a PubMed Central article. Click on link for full-text access.

APA Citation

Cook, N. R., Paynter, N. P., Manson, J. E., Martin, L. W., Robinson, J. G., Wassertheil-Smoller, S., & Ridker, P. M. (2012). Clinical utility of lipoprotein-associated phospholipase A2 for cardiovascular disease prediction in a multiethnic cohort of women. Clinical Chemistry, 58(9), 1352-1363.

Peer Reviewed

1

Open Access

1